|
|
M Sensi, C Farina, C Maccalli, R Lupetti, G Nicolini, A Anichini, G Parmiani, D Berd
J Clin Invest. 1997;
99(4):710
doi:10.1172/JCI119215
Abstract |
Full text
| PDF

M
etastatic melanoma patients treated with an autologous DNP-modified tumor cell vaccine develop inflammatory responses in metastatic tumors characterized by infiltration of CD8+ T cells. To further define this immune response, we analyzed T cell receptor beta-chain variable (TCRBV) region repertoire in biopsy specimens and peripheral blood lymphocytes of six patients. After administration of DNP vaccine, a restricted set of TCRBV gene families was found to be expanded compared with prevaccine metastases. In several postvaccine lesions of one patient, obtained over a 2-yr period, TCRBV14+ T cells were clonally expanded and identical T cell clonotypes could be detected. Two major recurring clones were biased toward the use of TCRBJ1S5. Furthermore, T cell lines derived from two such infiltrated skin lesions and, enriched in TCRBV14+ T cells, displayed HLA-class I-restricted lysis of the autologous melanoma cells. Clonal expansion of T cells was demonstrated in the T cell-infiltrated, postvaccine metastasis of a second patient as well. These results indicate that vaccination with autologous, DNP-modified melanoma cells can expand selected clones of T cells at the tumor site and that such clones are potentially destructive to the tumor.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(16)
| Title and authors |
Publication |
Year |
Autologous Versus Allogeneic Cell-Based Vaccines? :
Giorgio Parmiani, Lorenzo Pilla, Cristina Maccalli, Vincenzo Russo
|
The Cancer Journal
|
2011 |
Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients.
Mark R Albertini, Michael D Macklin, Cindy L Zuleger, Michael A Newton, Stephen A Judice, Richard J Albertini
|
Environ. Mol. Mutagen.
|
2008 |
Vaccination: role in metastatic melanoma
Lorenzo Pilla, Roberta Valenti, Andrea Marrari, Roberto Patuzzo, Mario Santinami, Giorgio Parmiani, Licia Rivoltini
|
Expert Rev Anticancer Ther
|
2006 |
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
Mohammad Reza Rezvany, Mahmood Jeddi Tehrani, Claes Karlsson, Jeanette Lundin, Hodjattallah Rabbani, Anders Österborg, Håkan Mellstedt
|
British Journal of Haematology
|
2006 |
T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody
Szilvia Mosolits, Katja Markovic, Jan Fagerberg, Jan-Erik Fr�din, Mohammad-Reza Rezvany, Shahryar Kiaii, H�kan Mellstedt, Mahmood Jeddi-Tehrani
|
Cancer Immunol Immunother
|
2004 |
Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial
Massimo Di Nicola, Carmelo Carlo-Stella, Andrea Anichini, Roberta Mortarini, Anna Guidetti, Gabrina Tragni, Francesco Gallino, Michele Del Vecchio, Fernando Ravagnani, Daniele Morelli, Paul Chaplin, Nathaly Arndtz, Gerd Sutter, Ingo Drexler, Giorgio Parmiani, Natale Cascinelli, Alessandro M. Gianni
|
Human Gene Therapy
|
2003 |
Synthetic and natural non-live vectors: rationale for their clinical development in cancer vaccine protocols
E Tartour, F Benchetrit, N Haicheur, O Adotevi, W.H Fridman
|
Vaccine
|
2002 |
M-Vax: an autologous, hapten-modified vaccine for human cancer
David Berd
|
Expert Opin. Biol. Ther.
|
2002 |
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, A. Anichini
|
JNCI Journal of the National Cancer Institute
|
2002 |
Autologous, hapten-modified vaccine as a treatment for human cancers
David Berd
|
Vaccine
|
2001 |
|